Welcome to our dedicated page for Phibro Animal Health Corporation news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health Corporation stock.
Phibro Animal Health Corporation (Class A, symbol: PAHC) is a leading global company specializing in animal health and mineral nutrition. With over 40 years of experience, Phibro is dedicated to meeting the rising demand for animal protein by focusing solely on animals used in food production. The company offers a comprehensive range of products for poultry, swine, beef and dairy cattle, and aquaculture.
Phibro's core business involves the development, manufacturing, and marketing of products designed to prevent, control, and treat animal diseases, enhance nutrition, and contribute to balanced mineral nutrition. Their product portfolio includes antibacterials, anticoccidials, nutritional specialty products, and vaccines. The company's operations are divided into three segments: Animal Health, Mineral Nutrition, and Performance Products, with the Animal Health segment being the primary revenue driver.
In the fiscal year ending June 30, 2017, Phibro reported net sales of $764 million. The company employs over 1,400 professionals who are committed to delivering value-based solutions to livestock producers, helping them maintain and enhance the health of their animals. Phibro's products are sold both in the United States and internationally, demonstrating its significant global footprint.
Recent achievements and ongoing projects by Phibro include the development of new vaccines and nutritional specialties aimed at improving animal health and productivity. The company continues to partner with various stakeholders in the livestock industry to innovate and provide sustainable solutions.
Phibro's financial condition remains robust, supported by consistent revenue streams from its diversified product offerings. The company’s focus on research and development underscores its commitment to advancing animal health technologies and addressing the evolving needs of the livestock industry.
For the latest news and updates, Phibro Animal Health Corporation remains a key player in the animal health sector, reflecting its dedication to enhancing the well-being of food animals globally.
Phibro Animal Health (Nasdaq: PAHC) has announced a quarterly cash dividend of $0.12 per share on both its Class A and Class B common stock. The dividend is set to be paid on September 25, 2024, to stockholders of record as of the close of business on September 4, 2024. This decision was made by the company's Board of Directors, demonstrating their commitment to returning value to shareholders. The consistent dividend payout suggests financial stability and confidence in the company's future performance.
Phibro Animal Health (Nasdaq: PAHC) has released its third annual Environmental, Social, and Governance (ESG) Report, highlighting 2023 achievements. The report emphasizes Phibro's commitment to enhancing animal health and nutrition to promote sustainability. Significant efforts include disease prevention, waste reduction, and resource conservation, which contribute to a safer, more affordable food supply. These initiatives align with the UN's 2030 Sustainable Development Goals (SDGs). The report underscores the importance of the One Health approach, emphasizing interconnections among the health of people, animals, and the planet. Phibro’s work in 2023 focused on reducing greenhouse gas emissions, enhancing food production efficiency, and supporting farmers' economic stability. This contributes to mitigating climate change and promoting food security. The company aims to continue driving sustainability and ethical growth, ensuring positive global contributions.
Phibro Animal Health (Nasdaq: PAHC) announced its participation in the Stifel Annual Dental and Animal Health (Jaws & Paws) Conference.
Key executives including CFO Glenn David, COO Larry Miller, and EVP Corporate Strategy Daniel Bendheim will present to financial analysts and investors on May 29, 2024, at 10:20 AM ET, at the St. Regis New York.
The live audio presentation will be accessible on the Phibro Animal Health Investor Relations Website, with a replay available for later viewing.
Phibro Animal Health reported strong financial results for the third quarter, with net sales increasing by 7% and adjusted EBITDA up by 9%. The company affirmed its fiscal year 2024 guidance, including net sales of $980 million to $1.020 billion and adjusted diluted EPS of $1.04 to $1.16. Phibro also updated its guidance for net income and diluted EPS due to recent developments.
Phibro Animal Health (PAHC) announced a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock, payable on June 26, 2024. The dividend will be distributed to stockholders of record as of June 5, 2024.
Zoetis Inc. (NYSE:ZTS) has entered into a definitive agreement with Phibro Animal Health (Nasdaq: PAHC), where the latter will acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products, and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024. The portfolio, generating approximately $400 million in revenue in 2023, comprises more than 37 product lines sold in around 80 countries, spanning across six manufacturing sites. More than 300 Zoetis colleagues will transition to Phibro Animal Health. The divestiture allows Zoetis to focus its livestock investments in other areas, such as vaccine, biologic, and genetic programs. The acquisition is expected to boost Phibro Animal Health’s sales and profitability significantly.
FAQ
What is the current stock price of Phibro Animal Health Corporation (PAHC)?
What is the market cap of Phibro Animal Health Corporation (PAHC)?
What does Phibro Animal Health Corporation do?
Which animals does Phibro's products cater to?
What are the main product categories of Phibro Animal Health Corporation?
How many employees does Phibro Animal Health Corporation have?
How much revenue did Phibro report for the fiscal year ending June 30, 2017?
What are the primary segments of Phibro's operations?
Where does Phibro sell its products?
What recent projects is Phibro involved in?
Who are Phibro's primary customers?
What drives Phibro's revenue?
